文献速递临床免疫质量管理与危急值

特应性皮炎免疫分析生物标志物的分析标准化与跨平台协调:挑战与临床实验室实施路线图

Analytical standardization and inter-platform harmonization of immunoassay-based biomarkers in atopic dermatitis: Challenges and a roadmap for clinical laboratory implementation.
PubMed 文献 · Clin Chim Acta · 2026-09-28

本综述系统分析了特应性皮炎(AD)免疫分析生物标志物(如TARC/CCL17、IL-13等)在临床实验室转化中面临的分析标准化与跨平台协调障碍,评估了不同免疫分析平台间的结果不可互换性,并提出了分阶段实现分析协调的路线图。

要点

  • AD免疫分析生物标志物缺乏分析标准化和跨平台协调,阻碍其常规临床应用。
  • 不同免疫分析平台检测原理、抗体对、校准品等差异导致结果常不可互换。
  • 需开发 certified 参考物质、EQA方案和共识性临床决策阈值以实现协调。

核心结论

  • AD免疫分析生物标志物在常规临床实验室应用中因缺乏分析标准化和跨平台协调而严重受限。

研究设计与样本

  • 本文为综述,系统检查了AD生物标志物免疫分析在诊断实验室医学框架下的分析和分析前障碍。

主要发现

  • 多种免疫分析平台(ELISA、Luminex、Olink、MSD、Simoa)在检测原理、抗体对、校准品、灵敏度范围和输出格式上差异显著,产生结果常不可互换。
  • 缺乏可交换参考物质、外部质量保证(EQA)方案和基于共识的AD特异性分析物临床决策阈值。
  • 新型样本基质(胶带剥离、微针皮肤液采集、汗液分析)存在独特的分析前挑战,影响测量变异性。
  • 需要年龄特异性和人群特异性参考区间,以应对AD在儿科和成人及不同种族间的异质性。

关键数值与推荐

  • 提出了分阶段路线图,包括系统方法比较研究、开发 certified 参考物质、建立专用EQA项目、多中心参考区间研究以及与即时检验和数字健康平台整合。

临床怎么用

  • 临床实验室应关注AD生物标志物检测的标准化进展,参与方法比较和EQA项目,以推动可重复的临床实验室报告。

局限性

  • 本文为综述,未报告原始研究数据;未涉及具体样本量、P值等数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunoassay-based biomarkers, including TARC/CCL17, IL-13, IL-22, IL-31, SCCA1/SCCA2, and periostin, have demonstrated clinical utility for severity assessment, therapeutic monitoring, and endotype classification in atopic dermatitis (AD). However, the translation of these biomarkers into routine clinical laboratory practice is critically hindered by the absence of analytical standardization and inter-platform harmonization. Multiple immunoassay platforms, including conventional ELISA, bead-based multiplex assays (Luminex), proximity extension assays (Olink), electrochemiluminescence (MSD), and ultra-sensitive digital immunoassays (Simoa), are employed across research and clinical settings. These platforms differ substantially in detection principles, antibody pairs, calibrator materials, sensitivity ranges, and output formats, generating results that are frequently non-interchangeable. This review systematically examines the analytical and preanalytical barriers to standardization of AD biomarker immunoassays within the framework of diagnostic laboratory medicine. We evaluate cross-platform concordance data, identify sources of inter-assay discordance, and analyze the current absence of commutable reference materials, external quality assurance (EQA) schemes, and consensus-based clinical decision thresholds for AD-specific analytes. Preanalytical challenges unique to novel sample matrices, including tape-strip sampling, microneedle-based skin fluid collection, and sweat analysis, are examined with respect to their impact on measurement variability. Age-specific and population-specific reference interval requirements are reviewed in the context of the known heterogeneity of AD across pediatric and adult populations and across ethnic groups. Finally, we propose a phased roadmap for achieving analytical harmonization, encompassing systematic method comparison studies, development of certified reference materials, establishment of dedicated EQA programs, multi-center reference interval studies, and integration with point-of-care and digital health platforms. This roadmap aims to bridge the gap between biomarker discovery and reproducible clinical laboratory reporting, thereby enabling the incorporation of standardized AD biomarker testing into precision dermatology workflows.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Tolibov M, Khamidova F, Toirov B, et al. Analytical standardization and inter-platform harmonization of immunoassay-based biomarkers in atopic dermatitis: Challenges and a roadmap for clinical laboratory implementation. Clin Chim Acta. 2026. PMID: 42805450. doi:10.1016/j.cca.2026.122860

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。